Bright Green Corporation and Asia Capital Pioneers Group (ACPG) launch an exclusive EB-5 offering to pioneer domestic production of plant-based drugs in the U.S.
Bright Green Corporation is breaking new ground in domestic production of plant-based medicines in the United States. Committed to sustainable high-tech agriculture, manufacturing, and research—a foundation built from a legacy of cannabis expertise and operations— Bright Green is a federally-authorized manufacturer of Active Pharmaceutical Ingredients (APIs) and plant-based drugs. With substantial ongoing support from the U.S. Congress to reduce reliance on foreign imports, Bright Green is at the forefront of the “Drugs Made in America” movement.
As operations expand at Bright Green’s 1 million sq ft Grants, New Mexico Facility to concentrate on the research, production, manufacture, and distribution of APIs, plant-based drugs, and Cannabis, compliance remains a key part of its ethos. Enabled by a New Mexico Board of Pharmacy application, and operating in full alignment with federal regulations including obtaining DEA registrations for new controlled substances, Bright Green has quickly emerged as a leader in the USD $27.97 Billion global plant-based API market—with a projected CAGR of 6% from 2023 to 2030.
As the sole business of this scale capable of meeting market demand, Bright Green is dedicated to securing long-term federal government contracts to establish a reliable domestic API supply chain, helping to diminish U.S. dependency on foreign drug imports and deliver exceptional value to shareholders.
USD $458,400,000
$800,000 + plus fees ($80,000 )
Equity ( $2.00 per share for $800,000 investment )
Regional Center Bright Green LLC
3 Years
USCIS Receipt Issued
Now available
